Skip to main content
Premium Trial:

Request an Annual Quote

DiagnoCure's Q2 Revenues Fall 85 Percent

NEW YORK (GenomeWeb News) – Canadian cancer diagnostics firm DiagnoCure reported after the close of the market on Monday that revenues for its fiscal second quarter fell 85 percent year over year.

Revenues for the three months ended April 30 were C$164,262 (US$159,770), compared to C$1.1 million in the second quarter of 2012. The drop-off was attributed largely to a payment from Hologic's Gen-Probe business of C$502,600 a year ago related to a US Food and Drug Administration milestone reached for Gen-Probe's Progensa PCA3 test, DiagnoCure said. Gen-Probe acquired the exclusive worldwide diagnostic rights to the PCA3 gene from DiagnoCure in late 2003.

The balance of the revenue decrease resulted from the termination of a development and licensing agreement with Signal Genetics. DiagnoCure said that the agreement, reached in 2011, was terminated this past January, and added at the time that it had regained all commercial rights and control of its intellectual property around its GCC biomarker, which was the basis of Signal Genetics' Previstage GCC colorectal cancer test.

The two firms also reached a settlement, under which Signal paid DiagnoCure US$200,000.

All revenues for the recently completed quarter were the result of royalty revenues from Gen-Probe and were down almost 3 percent from C$168,663 a year ago.

DiagnoCure's net loss for the quarter increased to C$849,344, or C$.02 per share, from a net loss of C$272,216, or C$.01 per share, a year ago.

Operating expenses before stock-based compensation, depreciation, and amortization was cut 26 percent to C$774,042 from C$1.1 a year ago.

The Quebec City, Quebec-based company finished the quarter with C$4.8 million in cash, cash equivalents, temporary, and long-term investments.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.